Ariz. Admin. Code § R9-6-391 - Syphilis
A. Case
control measures:
1. A syphilis case shall
obtain serologic testing for syphilis three months, six months, 12 months, and
24 months after initiating treatment, unless more frequent or longer testing is
recommended by a local health agency.
2. A health care provider shall order
serologic testing for syphilis for a pregnant individual at 28 to 32 weeks
gestation and at delivery.
3. A
local health agency shall:
a. Conduct an
epidemiologic investigation, including a review of medical records, of each
reported syphilis case or suspect case, confirming the stage of the
disease;
b. For each syphilis case,
submit to the Department, as specified in Table 2.4, the information required
under R9-6-206(D);
c. If the syphilis case is pregnant, ensure
that the syphilis case obtains the serologic testing for syphilis required in
subsections (A)(1) and (A)(2); and
d. Comply with the requirements specified in
R9-6-1103 concerning treatment and health education for a syphilis
case.
4. The operator of
a blood bank, blood center, or plasma center shall notify a donor of a test
result with significant evidence suggestive of syphilis, as required under
A.R.S. §
32-1483 and 21 CFR
630.6.
B. Contact control
measures: When a syphilis case has named a contact, a local health agency shall
comply with the requirements specified in R9-6-1103 concerning notification,
testing, treatment, and health education for the contact.
C. Outbreak control measures: A local health
agency shall:
1. Conduct an epidemiologic
investigation of each reported syphilis outbreak; and
2. For each syphilis outbreak, submit to the
Department the information required under R9-6-206(E).
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
Case control measures:
1. A diagnosing health care provider or an administrator of a health care institution, either personally or through a representative, shall isolate and implement contact precautions for a case or suspect case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus.
2. A diagnosing health care provider or an administrator of a health care institution transferring a known case with active infection or a known carrier of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus to another health care provider or health care institution shall, either personally or through a representative, comply with R9-6-305.
a. Upon receiving a report under R9-6-202 of a case or suspect case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus, notify the Department within one working day after receiving the report and provide to the Department the information contained in the report;
b. Ensure that a case or suspect case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus is isolated as necessary to prevent transmission;
c. Conduct an epidemiologic investigation of each reported case or suspect case of vancomycin-resistant or vancomycin-inter-mediate Staphylococcus aureus;
d. For each case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus, submit to the Department, as specified in Table 2.4, the information required under R9-6-206(D); and
e. Ensure that an isolate or a specimen, as available, from each case of vancomycin-resistant or vancomycin-intermediate Staphylococcus aureus is submitted to the Arizona State Laboratory.